The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Unlike the brand-name drugs Ozempic, Wegovy, Mounjaro, and Zepbound, compounded versions haven’t been rigorously tested in ...

As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.

Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health ...

Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it ...

Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.

Government health plans in the U.S. provide significant coverage for new weight-loss drugs, overshadowing private insurers.